Compare TSI & PROF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | TSI | PROF |
|---|---|---|
| Founded | 1987 | N/A |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Investment Managers | Medical/Dental Instruments |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 276.5M | 248.8M |
| IPO Year | 1995 | 2017 |
| Metric | TSI | PROF |
|---|---|---|
| Price | $4.30 | $7.06 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $11.14 |
| AVG Volume (30 Days) | 110.9K | ★ 178.9K |
| Earning Date | 01-01-0001 | 11-05-2026 |
| Dividend Yield | ★ 7.46% | N/A |
| EPS Growth | N/A | ★ 25.89 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $16,098,000.00 |
| Revenue This Year | N/A | $61.76 |
| Revenue Next Year | N/A | $70.98 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 50.73 |
| 52 Week Low | $4.11 | $4.91 |
| 52 Week High | $4.98 | $8.95 |
| Indicator | TSI | PROF |
|---|---|---|
| Relative Strength Index (RSI) | 51.51 | 54.31 |
| Support Level | $4.14 | $6.44 |
| Resistance Level | $4.45 | $7.19 |
| Average True Range (ATR) | 0.07 | 0.55 |
| MACD | -0.00 | 0.01 |
| Stochastic Oscillator | 36.84 | 53.92 |
Tcw Strategic Income Fund Inc operates as a diversified closed-end management investment company. The investment objective of the company is to seek a total return comprised of current income and capital appreciation by investing in a wide range of securities. The company invests in a range of industries, such as banks, beverages, biotechnology, chemicals, commercial services, and others.
Profound Medical Corp is a commercial-stage medical device company focused on the development and marketing of AI-powered, MRI-guided, incision-free therapies for the ablation of diseased tissue. The company's flagship product, the TULSA-PRO system, combines real-time MRI, robotically-driven transurethral sweeping action/thermal ultrasound and closed-loop temperature feedback control to ablate whole gland or physician defined region of malignant or benign prostate tissue. Its platform technologies combine imaging, robotic control, and ultrasound-based thermal ablation for the treatment of prostate conditions. The company generates revenue through the sale of capital equipment and recurring sales of single-use devices and related services used in patient treatments.